Natera (NASDAQ:NTRA) Insider John Fesko Sells 339 Shares

Key Points

• John Fesko, an insider at Natera, sold 339 shares of the company on October 21st for approximately $63,715, reducing his holdings to 152,408 shares.
• Natera's stock performance showed a slight increase, trading up to $188.02, with a year high of $196.63 and a year low of $117.27.
• The company reported a revenue increase of 32.2% year-over-year, with earnings per share at ($0.74) for the latest quarter, missing analysts' estimates.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 339 shares of the stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $187.95, for a total transaction of $63,715.05. Following the transaction, the insider directly owned 152,408 shares of the company's stock, valued at approximately $28,645,083.60. This trade represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

John Fesko also recently made the following trade(s):

• On Thursday, August 14th, John Fesko sold 678 shares of Natera stock. The stock was sold at an average price of $155.46, for a total transaction of $105,401.88.
• On Monday, July 28th, John Fesko sold 1,710 shares of Natera stock. The shares were sold at an average price of $139.81, for a total transaction of $239,075.10.

Natera Stock Performance

NTRA traded up $1.14 during trading on Wednesday, hitting $188.02. The stock had a trading volume of 1,333,479 shares, compared to its average volume of 1,160,110. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $196.63. The firm has a market capitalization of $25.81 billion, a P/E ratio of -98.44 and a beta of 1.74. The company's 50-day moving average price is $169.97 and its 200 day moving average price is $159.37.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same period in the previous year, the company posted ($0.30) earnings per share. Natera's revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Institutional investors have recently modified their holdings of the business. Guided Capital Wealth Management LLC boosted its position in shares of Natera by 0.5% during the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company's stock valued at $2,219,000 after purchasing an additional 66 shares in the last quarter. Main Management ETF Advisors LLC grew its holdings in Natera by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company's stock valued at $743,000 after purchasing an additional 72 shares during the period. Yousif Capital Management LLC grew its position in shares of Natera by 4.5% in the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company's stock valued at $271,000 after purchasing an additional 72 shares in the last quarter. Wedmont Private Capital boosted its stake in Natera by 4.9% during the second quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company's stock valued at $256,000 after buying an additional 74 shares during the period. Finally, Gries Financial LLC boosted its stake in Natera by 4.0% during the third quarter. Gries Financial LLC now owns 1,904 shares of the medical research company's stock valued at $306,000 after buying an additional 74 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on NTRA. Weiss Ratings restated a "sell (d-)" rating on shares of Natera in a research note on Wednesday, October 8th. Wells Fargo & Company began coverage on Natera in a research note on Monday, September 22nd. They issued an "equal weight" rating and a $175.00 price target for the company. Stephens reaffirmed an "overweight" rating and set a $183.00 target price on shares of Natera in a research report on Friday, August 15th. Canaccord Genuity Group restated a "buy" rating and issued a $200.00 target price on shares of Natera in a research note on Tuesday, October 14th. Finally, Zacks Research cut Natera from a "hold" rating to a "strong sell" rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $196.81.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.